Exploiting evolutionary steering to induce collateral drug sensitivity in cancer.

Antineoplastic Agents / pharmacology Clonal Evolution Computational Biology Computer Simulation Drug Resistance, Neoplasm Evolution, Molecular Gefitinib / pharmacology Genotype Humans Lung Neoplasms / drug therapy Models, Theoretical Molecular Medicine Pyridones / pharmacology Pyrimidinones / pharmacology Stochastic Processes

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
21 04 2020
Historique:
received: 08 10 2019
accepted: 18 03 2020
entrez: 23 4 2020
pubmed: 23 4 2020
medline: 4 8 2020
Statut: epublish

Résumé

Drug resistance mediated by clonal evolution is arguably the biggest problem in cancer therapy today. However, evolving resistance to one drug may come at a cost of decreased fecundity or increased sensitivity to another drug. These evolutionary trade-offs can be exploited using 'evolutionary steering' to control the tumour population and delay resistance. However, recapitulating cancer evolutionary dynamics experimentally remains challenging. Here, we present an approach for evolutionary steering based on a combination of single-cell barcoding, large populations of 10

Identifiants

DOI: 10.1038/s41467-020-15596-z PMID: 32317663 PMC: PMC7174377
pubmed: 32317663
doi: 10.1038/s41467-020-15596-z
pii: 10.1038/s41467-020-15596-z
pmc: PMC7174377
doi:

Substances chimiques

Antineoplastic Agents 0
Pyridones 0
Pyrimidinones 0
trametinib 33E86K87QN
Gefitinib S65743JHBS

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1923

Subventions

Organisme : Department of Health
ID : RP-2016-07-28
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA185138
Pays : United States
Organisme : Wellcome Trust
ID : 202778/B/16/Z
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A22897
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A18052
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P01 CA091955
Pays : United States
Organisme : Wellcome Trust
ID : 105104/Z/14/Z
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA170595
Pays : United States
Organisme : Cancer Research UK
ID : 11566
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A22909
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA140657
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA217376
Pays : United States
Organisme : Cancer Research UK
ID : A23110
Pays : United Kingdom
Organisme : DH | National Institute for Health Research (NIHR)
ID : RP-2016-07-28
Pays : International
Organisme : Cancer Research UK
ID : A25128
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A26815
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 202778/Z/16/Z
Pays : United Kingdom
Organisme : Department of Health
ID : RP-2016-07-028
Pays : United Kingdom

Références

Zhang, J., Yang, P. L. & Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28–39 (2009).
pubmed: 19104514 doi: 10.1038/nrc2559
Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714–726 (2013).
pubmed: 24060863 pmcid: 24060863 doi: 10.1038/nrc3599
Meacham, C. E. & Morrison, S. J. Tumour heterogeneity and cancer cell plasticity. Nature 501, 328–337 (2013).
pubmed: 24048065 pmcid: 4521623 doi: 10.1038/nature12624
McGranahan, N. & Swanton, C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27, 15–26 (2015).
pubmed: 25584892 doi: 10.1016/j.ccell.2014.12.001
Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).
pubmed: 15737014 pmcid: 549606 doi: 10.1371/journal.pmed.0020073
Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69–80 (2010).
pubmed: 20371346 pmcid: 2851638 doi: 10.1016/j.cell.2010.02.027
Shaffer, S. M. et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature 546, 431–435 (2017).
pubmed: 28607484 pmcid: 5542814 doi: 10.1038/nature22794
Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532–536 (2012).
pubmed: 22722830 pmcid: 3927413 doi: 10.1038/nature11156
Diaz, L. A. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537–540 (2012).
pubmed: 22722843 pmcid: 3436069 doi: 10.1038/nature11219
Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306–313 (2012).
pubmed: 22258609 pmcid: 22258609 doi: 10.1038/nature10762
Burrell, R. A. & Swanton, C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol. Oncol. 8, 1095–1111 (2014).
pubmed: 25087573 pmcid: 5528620 doi: 10.1016/j.molonc.2014.06.005
Nichol, D., Robertson-Tessi, M., Jeavons, P. & Anderson, A. R. A. Stochasticity in the genotype–phenotype map: implications for the robustness and persistence of bet-hedging. Genetics 204, 1523–1539 (2016).
pubmed: 27770034 pmcid: 5161283 doi: 10.1534/genetics.116.193474
Hata, A. N. et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22, 262–269 (2016).
pubmed: 26828195 pmcid: 4900892 doi: 10.1038/nm.4040
Hall, M. D., Handley, M. D. & Gottesman, M. M. Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol. Sci. 30, 546–556 (2009).
pubmed: 19762091 pmcid: 2774243 doi: 10.1016/j.tips.2009.07.003
Luria, S. E. & Delbrück, M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28, 491–511 (1943).
pubmed: 17247100 pmcid: 1209226
Gillies, R. J., Verduzco, D. & Gatenby, R. A. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat. Rev. Cancer 12, 487–493 (2012).
pubmed: 22695393 pmcid: 4122506 doi: 10.1038/nrc3298
Imamovic, L. & Sommer, M. O. A. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci. Transl. Med. 5, 204ra132–204ra132 (2013).
pubmed: 24068739 doi: 10.1126/scitranslmed.3006609
Pál, C., Papp, B. & Lázár, V. Collateral sensitivity of antibiotic-resistant microbes. Trends Microbiol. 23, 401–407 (2015).
pubmed: 25818802 pmcid: 5958998 doi: 10.1016/j.tim.2015.02.009
Nichol, D. et al. Steering evolution with sequential therapy to prevent the emergence of bacterial antibiotic resistance. PLoS Comput. Biol. 11, e1004493 (2015).
pubmed: 26360300 pmcid: 4567305 doi: 10.1371/journal.pcbi.1004493
Kirkman, L. A. et al. Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance. Proc. Natl Acad. Sci. USA 115, 201806109–E6870 (2018).
doi: 10.1073/pnas.1806109115
Zhao, B. et al. Exploiting temporal collateral sensitivity in tumor clonal evolution. Cell 165, 1–13 (2016).
doi: 10.1016/j.cell.2016.03.013
Wang, L. et al. An acquired vulnerability of drug-resistant melanoma with therapeutic potential. Cell 173, 1413–1425.e14 (2018).
pubmed: 29754815 doi: 10.1016/j.cell.2018.04.012 pmcid: 29754815
Merlo, L. M. F., Pepper, J. W., Reid, B. J. & Maley, C. C. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 6, 924–935 (2006).
pubmed: 17109012 doi: 10.1038/nrc2013 pmcid: 17109012
Gatenby, R. A., Silva, A. S., Gillies, R. J. & Frieden, B. R. Adaptive therapy. Cancer Res. 69, 4894–4903 (2009).
pubmed: 19487300 pmcid: 3728826 doi: 10.1158/0008-5472.CAN-08-3658
Gatenby, R. A., Brown, J. & Vincent, T. Lessons from applied ecology: cancer control using an evolutionary double bind. Cancer Res. 69, 7499–7502 (2009).
pubmed: 19752088 doi: 10.1158/0008-5472.CAN-09-1354 pmcid: 19752088
Basanta, D., Gatenby, R. A. & Anderson, A. R. A. Exploiting evolution to treat drug resistance: combination therapy and the double bind. Mol. Pharmaceutics 9, 914–921 (2012).
doi: 10.1021/mp200458e
Hughes, D. & Andersson, D. I. Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nat. Rev. Genet. 16, 459–471 (2015).
pubmed: 26149714 doi: 10.1038/nrg3922 pmcid: 26149714
Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795–801 (2015).
pubmed: 26030179 pmcid: 4868598 doi: 10.1038/nm.3870
Xue, Y. et al. An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. Nat. Med. 23, 929–937 (2017).
pubmed: 28714990 pmcid: 5696266 doi: 10.1038/nm.4369
Pluchino, K. M., Hall, M. D., Goldsborough, A. S., Callaghan, R. & Gottesman, M. M. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist. Updat. 15, 98–105 (2012).
pubmed: 22483810 pmcid: 3348266 doi: 10.1016/j.drup.2012.03.002
Zhao, B., Hemann, M. T. & Lauffenburger, D. A. Modeling tumor clonal evolution for drug combinations design. Trends Cancer 2, 144–158 (2016).
pubmed: 28435907 pmcid: 5400294 doi: 10.1016/j.trecan.2016.02.001
Turajlic, S., Sottoriva, A., Graham, T. & Swanton, C. Resolving genetic heterogeneity in cancer. Nat. Rev. Genet. 27, 1 (2019).
Machioka, K. et al. Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines. Oncotarget 9, 16185–16196 (2018).
pubmed: 29662635 pmcid: 5882326 doi: 10.18632/oncotarget.24609
Fuentes-Hernandez, A. et al. Using a sequential regimen to eliminate bacteria at sublethal antibiotic dosages. PLoS Biol. 13, e1002104 (2015).
pubmed: 25853342 pmcid: 4390231 doi: 10.1371/journal.pbio.1002104
Hata, A. N. et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22, 262–269 (2016).
pubmed: 26828195 pmcid: 4900892 doi: 10.1038/nm.4040
Shibue, T. & Weinberg, R. A. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 14, 611–629 (2017).
pubmed: 28397828 pmcid: 5720366 doi: 10.1038/nrclinonc.2017.44
Raoof, S. et al. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene 350, 1–15 (2019).
Gottesman, M. M. & Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385–427 (1993).
pubmed: 8102521 doi: 10.1146/annurev.bi.62.070193.002125 pmcid: 8102521
Wright, S. The roles of mutation, inbreeding, crossbreeding and selection in evolution. In Proc. Sixth International Congress of Genetics, Vol. 1, 356–366 (1932).
Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039–1043 (2007).
pubmed: 17463250 doi: 10.1126/science.1141478
Bhang, H.-E. C. et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat. Med. 21, 440–448 (2015).
pubmed: 25849130 doi: 10.1038/nm.3841
Van Emburgh, B. O. et al. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat. Commun. 7, 283ra254 (2016).
Domínguez-Vigil, I. G., Moreno-Martínez, A. K., Wang, J. Y., Roehrl, M. H. A. & Barrera-Saldaña, H. A. The dawn of the liquid biopsy in the fight against cancer. Oncotarget 9, 2912–2922 (2018).
pubmed: 29416824 doi: 10.18632/oncotarget.23131
Mullighan, C. G., Williams, R. T., Downing, J. R. & Sherr, C. J. Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes Dev. 22, 1411–1415 (2008).
pubmed: 18519632 pmcid: 2732413 doi: 10.1101/gad.1673908
Dongre, A. & Weinberg, R. A. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 20, 69–84 (2019). 2018 20:2.
pubmed: 30459476 doi: 10.1038/s41580-018-0080-4
Greve, G. et al. The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells. BMC Cancer 15, 1–10 (2015).
doi: 10.1186/s12885-015-1967-5
Damaskos, C. et al. Histone deacetylase inhibitors as a novel targeted therapy against non-small cell lung cancer: where are we now and what should we expect? Anticancer Res. 38, 37–43 (2018).
pubmed: 29277754
Gautschi, O., Mack, P. C., Davies, A. M., Lara, P. N. Jr & Gandara, D. R. Aurora kinase inhibitors: a new class of targeted drugs in cancer. Clin. Lung Cancer 8, 93–98 (2006).
pubmed: 17026809 doi: 10.3816/CLC.2006.n.036
Shah, K. N. et al. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nat. Med. 25, 111–118 (2019).
pubmed: 30478424 doi: 10.1038/s41591-018-0264-7
Delbaldo, C. et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 292, 470–484 (2004).
pubmed: 15280345 doi: 10.1001/jama.292.4.470
Carrick, S. et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst. Rev. 34, 27 (2009).
Ghosn, J., Taiwo, B., Seedat, S., Autran, B. & Katlama, C. HIV. The Lancet https://doi.org/10.1016/S0140-6736(18)31311-4 (2018).
Alto, B. W., Lampman, R. L., Kesavaraju, B. & Muturi, E. J. Pesticide-induced release from competition among competing Aedes aegypti and Aedes albopictus (Diptera: Culicidae). J. Med. Entomol. 50, 1240–1249 (2013).
pubmed: 24843928 doi: 10.1603/ME12135
Neve, P., Vila-Aiub, M. & Roux, F. Evolutionary-thinking in agricultural weed management. N. Phytol. 184, 783–793 (2009).
doi: 10.1111/j.1469-8137.2009.03034.x
Oliveira, E. E., Guedes, R. N. C., Tótola, M. R. & De Marco, P. Jr. Competition between insecticide-susceptible and -resistant populations of the maize weevil, Sitophilus zeamais. Chemosphere 69, 17–24 (2007).
pubmed: 17570459 doi: 10.1016/j.chemosphere.2007.04.077
Enriquez-Navas, P. M. et al. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci. Transl. Med. 8, 327ra24 (2016).
pubmed: 26912903 pmcid: 4962860 doi: 10.1126/scitranslmed.aad7842
Gallaher, J. A., Enriquez-Navas, P. M., Luddy, K. A., Gatenby, R. A. & Anderson, A. R. A. Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies. Cancer Res. 78, 2127–2139 (2018).
pubmed: 29382708 pmcid: 5899666 doi: 10.1158/0008-5472.CAN-17-2649
Zhang, J., Cunningham, J. J., Brown, J. S. & Gatenby, R. A. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat. Commun. 8, 1816 (2017).
pubmed: 29180633 pmcid: 5703947 doi: 10.1038/s41467-017-01968-5
Staňková, K., Brown, J. S., Dalton, W. S. & Gatenby, R. A. Optimizing cancer treatment using game theory: a review. JAMA Oncol. 5, 96–103 (2018).
Vlachogiannis, G. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359, 920–926 (2018).
pubmed: 29472484 pmcid: 6112415 doi: 10.1126/science.aao2774
Erban, R., Chapman, S. J. Stochastic modelling of reaction-diffusion processes (Cambridge Texts in Applied Mathematics). Cam. Uni. Press (2020).
Mumenthaler, S. M. et al. The impact of microenvironmental heterogeneity on the evolution of drug resistance in cancer cells. Cancer Inform. 14s4, CIN.S19338 (2015).
doi: 10.4137/CIN.S19338
Rimmer, A. et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat. Genet. 46, 912–918 (2014).
pubmed: 4753679 pmcid: 4753679 doi: 10.1038/ng.3036
Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308–311 (2001).
pubmed: 11125122 pmcid: 29783 doi: 10.1093/nar/29.1.308
Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proc. Natl Acad. Sci. USA 107, 16910–16915 (2010).
pubmed: 20837533 doi: 10.1073/pnas.1009843107 pmcid: 20837533
Favero, F. et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann. Oncol. 26, 64–70 (2014).
pubmed: 25319062 pmcid: 4269342 doi: 10.1093/annonc/mdu479
Torre, E. et al. Rare cell detection by single-cell RNA sequencing as guided by single-molecule RNA FISH. Cell Syst. 6, 171–179.e5 (2018).
pubmed: 29454938 pmcid: 6078200 doi: 10.1016/j.cels.2018.01.014
Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018).
pubmed: 29608179 pmcid: 29608179 doi: 10.1038/nbt.4096
Lin, Y. et al. Evaluating stably expressed genes in single cells. GigaScience 8, 1–10 (2019).
doi: 10.1093/gigascience/giz106

Auteurs

Ahmet Acar (A)

Evolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Department of Biological Sciences, Middle East Technical University, Ankara, Turkey.

Daniel Nichol (D)

Evolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
ORCID: 0000-0003-2662-1836

Javier Fernandez-Mateos (J)

Evolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.

George D Cresswell (GD)

Evolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
ORCID: 0000-0003-3303-068X

Iros Barozzi (I)

Department of Surgery and Cancer, Imperial College London, London, UK.

Sung Pil Hong (SP)

Department of Surgery and Cancer, Imperial College London, London, UK.

Nicholas Trahearn (N)

Evolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.

Inmaculada Spiteri (I)

Evolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
ORCID: 0000-0002-1097-8972

Mark Stubbs (M)

CRUK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK.

Rosemary Burke (R)

CRUK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK.

Adam Stewart (A)

Clinical Pharmacology-Adaptive Therapy Group, Division of Cancer Therapeutics and Clinical Studies, The Institute of Cancer Research, London, UK.

Giulio Caravagna (G)

Evolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.

Benjamin Werner (B)

Evolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
ORCID: 0000-0002-6857-8699

Georgios Vlachogiannis (G)

Gastrointestinal Cancer Biology and Genomics Team, Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
ORCID: 0000-0003-3114-8772

Carlo C Maley (CC)

Arizona Cancer Evolution Center, Biodesign Institute, Arizona State University, Tempe, USA.
ORCID: 0000-0002-0745-7076

Luca Magnani (L)

Department of Surgery and Cancer, Imperial College London, London, UK.
ORCID: 0000-0002-7534-0785

Nicola Valeri (N)

Gastrointestinal Cancer Biology and Genomics Team, Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK.

Udai Banerji (U)

CRUK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. udai.banerji@icr.ac.uk.
Clinical Pharmacology-Adaptive Therapy Group, Division of Cancer Therapeutics and Clinical Studies, The Institute of Cancer Research, London, UK. udai.banerji@icr.ac.uk.
Drug Development Unit, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London, UK. udai.banerji@icr.ac.uk.
ORCID: 0000-0003-1503-3123

Andrea Sottoriva (A)

Evolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK. andrea.sottoriva@icr.ac.uk.
ORCID: 0000-0001-6709-9533

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Exploiting evolutionary steering to induce...
questionsmedicales.fr › Phénomènes génétiques › Évolution clonale › Exploiting evolutionary steering to induce...
questionsmedicales.fr › Sciences de l'information › Informatique › Biologie informatique › Exploiting evolutionary steering to induce...
questionsmedicales.fr › Sciences de l'information › Méthodologies informatiques › Simulation numérique › Exploiting evolutionary steering to induce...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › Exploiting evolutionary steering to induce...
questionsmedicales.fr › Phénomènes biologiques › Évolution biologique › Évolution moléculaire › Exploiting evolutionary steering to induce...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinazolines › Géfitinib › Exploiting evolutionary steering to induce...
questionsmedicales.fr › Phénomènes génétiques › Génotype › Exploiting evolutionary steering to induce...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Exploiting evolutionary steering to induce...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Exploiting evolutionary steering to induce...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Exploiting evolutionary steering to induce...
questionsmedicales.fr › Professions de santé › Médecine › Médecine moléculaire › Exploiting evolutionary steering to induce...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Pyridones › Exploiting evolutionary steering to induce...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Pyrimidinones › Exploiting evolutionary steering to induce...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Processus stochastiques › Exploiting evolutionary steering to induce...